162 related articles for article (PubMed ID: 32566919)
1. Distinguishing Pharmacokinetics of Marketed Nanomedicine Formulations Using a Stable Isotope Tracer Assay.
Skoczen SL; Snapp KS; Crist RM; Kozak D; Jiang X; Liu H; Stern ST
ACS Pharmacol Transl Sci; 2020 Jun; 3(3):547-558. PubMed ID: 32566919
[TBL] [Abstract][Full Text] [Related]
2. Bioequivalence assessment of high-capacity polymeric micelle nanoformulation of paclitaxel and Abraxane® in rodent and non-human primate models using a stable isotope tracer assay.
Hwang D; Vinod N; Skoczen SL; Ramsey JD; Snapp KS; Montgomery SA; Wang M; Lim C; Frank JE; Sokolsky-Papkov M; Li Z; Yuan H; Stern ST; Kabanov AV
Biomaterials; 2021 Nov; 278():121140. PubMed ID: 34634661
[TBL] [Abstract][Full Text] [Related]
3. Improved Ultrafiltration Method to Measure Drug Release from Nanomedicines Utilizing a Stable Isotope Tracer.
Skoczen SL; Stern ST
Methods Mol Biol; 2018; 1682():223-239. PubMed ID: 29039106
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Temperature-Dependent Drug Release of Solubilizing Nanoformulations Using the SITUA.
Stern ST; Skoczen SL; Park YH
Methods Mol Biol; 2024; 2789():301-311. PubMed ID: 38507012
[TBL] [Abstract][Full Text] [Related]
5. Stable isotope method to measure drug release from nanomedicines.
Skoczen S; McNeil SE; Stern ST
J Control Release; 2015 Dec; 220(Pt A):169-174. PubMed ID: 26596375
[TBL] [Abstract][Full Text] [Related]
6. A physiologically-based nanocarrier biopharmaceutics model to reverse-engineer the in vivo drug release.
Nagpal S; Braner S; Modh H; Tan AXX; Mast MP; Chichakly K; Albrecht V; Wacker MG
Eur J Pharm Biopharm; 2020 Aug; 153():257-272. PubMed ID: 32589926
[TBL] [Abstract][Full Text] [Related]
7. What nanomedicine in the clinic right now really forms nanoparticles?
Svenson S
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2014; 6(2):125-35. PubMed ID: 24415653
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
[TBL] [Abstract][Full Text] [Related]
9. Albumin Nanoparticles Increase the Efficacy of Doxorubicin Hydrochloride Liposome Injection Based on Threshold Theory.
Lin W; Li A; Qiu L; Huang H; Cui P; Wang J
Mol Pharm; 2024 Jun; 21(6):2970-2980. PubMed ID: 38742943
[TBL] [Abstract][Full Text] [Related]
10. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy.
Kim SC; Kim DW; Shim YH; Bang JS; Oh HS; Wan Kim S; Seo MH
J Control Release; 2001 May; 72(1-3):191-202. PubMed ID: 11389998
[TBL] [Abstract][Full Text] [Related]
11. When Is It Important to Measure Unbound Drug in Evaluating Nanomedicine Pharmacokinetics?
Stern ST; Martinez MN; Stevens DM
Drug Metab Dispos; 2016 Dec; 44(12):1934-1939. PubMed ID: 27670412
[TBL] [Abstract][Full Text] [Related]
12. Thermoreversible Pluronic F127-based hydrogel containing liposomes for the controlled delivery of paclitaxel: in vitro drug release, cell cytotoxicity, and uptake studies.
Nie S; Hsiao WL; Pan W; Yang Z
Int J Nanomedicine; 2011; 6():151-66. PubMed ID: 21499415
[TBL] [Abstract][Full Text] [Related]
13. Bioequivalence of paclitaxel protein-bound particles in patients with breast cancer: determining total and unbound paclitaxel in plasma by rapid equilibrium dialysis and liquid chromatography-tandem mass spectrometry.
Li J; Li W; Dai X; Zhong D; Ding Y; Chen X
Drug Des Devel Ther; 2019; 13():1739-1749. PubMed ID: 31190752
[No Abstract] [Full Text] [Related]
14. The Uniqueness of Albumin as a Carrier in Nanodrug Delivery.
Spada A; Emami J; Tuszynski JA; Lavasanifar A
Mol Pharm; 2021 May; 18(5):1862-1894. PubMed ID: 33787270
[TBL] [Abstract][Full Text] [Related]
15. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol).
Sparreboom A; Scripture CD; Trieu V; Williams PJ; De T; Yang A; Beals B; Figg WD; Hawkins M; Desai N
Clin Cancer Res; 2005 Jun; 11(11):4136-43. PubMed ID: 15930349
[TBL] [Abstract][Full Text] [Related]
16. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes.
Gabizon A; Catane R; Uziely B; Kaufman B; Safra T; Cohen R; Martin F; Huang A; Barenholz Y
Cancer Res; 1994 Feb; 54(4):987-92. PubMed ID: 8313389
[TBL] [Abstract][Full Text] [Related]
17. Comparative in vitro properties and clinical pharmacokinetics of Paclitaxel following the administration of taxol(r) and paxene(r).
Scripture CD; Szebeni J; Loos WJ; Figg WD; Sparreboom A
Cancer Biol Ther; 2005 May; 4(5):555-60. PubMed ID: 15917657
[TBL] [Abstract][Full Text] [Related]
18. Rapid Analysis of DOXIL Stability and Drug Release from DOXIL by HPLC Using a Glycidyl Methacrylate-Coated Monolithic Column.
Kimoto A; Watanabe A; Yamamoto E; Higashi T; Kato M
Chem Pharm Bull (Tokyo); 2017; 65(10):945-949. PubMed ID: 28966279
[TBL] [Abstract][Full Text] [Related]
19. Polymer nanomedicines based on micelle-forming amphiphilic or water-soluble polymer-doxorubicin conjugates: Comparative study of in vitro and in vivo properties related to the polymer carrier structure, composition, and hydrodynamic properties.
Braunová A; Chytil P; Laga R; Šírová M; Machová D; Parnica J; Říhová B; Janoušková O; Etrych T
J Control Release; 2020 May; 321():718-733. PubMed ID: 32142741
[TBL] [Abstract][Full Text] [Related]
20. Drug release from nanomedicines: Selection of appropriate encapsulation and release methodology.
Wallace SJ; Li J; Nation RL; Boyd BJ
Drug Deliv Transl Res; 2012 Aug; 2(4):284-92. PubMed ID: 23110256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
